Scinai Immunotherapeutics (SCNI) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Scinai Immunotherapeutics Ltd., a biopharmaceutical company, has restructured a significant bank loan into equity to secure its Nasdaq listing compliance, expected by August 23, 2024. The company also reported confidence in their contract development and manufacturing organization (CDMO) services, with projected sales growth following positive market engagement and development milestones in its pipeline, including promising results for a psoriasis treatment and strategic partnership pursuits for its NanoAb therapies.
For further insights into SCNI stock, check out TipRanks’ Stock Analysis page.
